PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New Drug ...

The International Society for Pharmaceutical Engineering (ISPE) has recognized Eli Lilly Kinsale Limited as the Overall Winner of the 2024 Facility of the Year Awards (FOYA) for its IE2b facility ...

PTC Therapeutics Inc. (PTCT) announced that the FDA has set a target action date of July 29, 2025, for the review of the New Drug ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New Drug Application (NDA) for sepiapterin, ...

Artera, the SaaS digital health leader in patient communications, recently unveiled a suite of new product innovations ...

PTC Therapeutics (NASDAQ:PTCT) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for sepiapterin, an experimental therapy for a brain disorder ...

PTC Therapeutics (NASDAQ:PTCT) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted its marketing ...

WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of ...

(RTTNews) - PTC Therapeutics (PTCT) announced the FDA has accepted for filing the New Drug Application of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with ...